Durham, NC, USA and SEOUL, South Korea, November 17, 2025 — Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services,...

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, November 7, 2025 — Lunit (KRX:328130.KQ), a...

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, announced on May 23 that 12 studies featuring its AI-powered digital pathology solution will be presented at the 2025 American Society of Clinical Oncology...

SimonMed Imaging and Lunit: A Major Leap Forward in Patient Health and the Future of Mammography PHOENIX, April 23, 2025 /PRNewswire/ -- SimonMed Imaging®, one of the largest and most advanced outpatient medical imaging providers in the...

SEOUL, South Korea, April 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven posters at the American Association for...

Lunit: AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea, March 26,...